Literature DB >> 22278702

Intraductal papillary mucinous neoplasms of the pancreas: making a disposition using the natural history.

L William Traverso1, Toshiyuki Moriya, Yasushi Hashimoto.   

Abstract

The process of Intraductal papillary mucinous neoplasms (IPMN) follows the adenoma-to-carcinoma sequence. If it progresses to malignancy about 5 years is required. Even though the process is slow IPMN provides the clinician with the opportunity to avoid malignancy if the patient is at risk. The natural history as observed through Kaplan Meier event curves for occurrence of malignancy show the process to malignancy is much faster (50% within 2 years) if pancreatitis-like symptoms are present or if the main pancreatic duct (MPD) is involved. Almost all decisions to resect (95% in our experience) are based on the presence of symptoms or the MPD location. Cyst size is used infrequently. Every patient with an IPMN should always have a planned follow-up and the frequency depends on the perceived risk of malignancy-immediate imaging if becomes symptomatic to every 2 to 3 years if asymptomatic side branch lesions. The natural history provides modern guidelines for making decisions in patients with a newly discovered IPMN.

Entities:  

Mesh:

Year:  2012        PMID: 22278702     DOI: 10.1007/s11894-012-0239-7

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  13 in total

1.  Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct.

Authors:  B Terris; P Ponsot; F Paye; P Hammel; A Sauvanet; G Molas; P Bernades; J Belghiti; P Ruszniewski; J F Fléjou
Journal:  Am J Surg Pathol       Date:  2000-10       Impact factor: 6.394

Review 2.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

3.  Incidence of pancreatic anastomotic failure and delayed gastric emptying after pancreatoduodenectomy in 507 consecutive patients: use of a web-based calculator to improve homogeneity of definition.

Authors:  Yasushi Hashimoto; L William Traverso
Journal:  Surgery       Date:  2009-12-16       Impact factor: 3.982

4.  The duration of symptoms predicts the presence of malignancy in 210 resected cases of pancreatic intraductal papillary mucinous neoplasms.

Authors:  Toshiyuki Moriya; Yasushi Hashimoto; L William Traverso
Journal:  J Gastrointest Surg       Date:  2011-03-05       Impact factor: 3.452

5.  Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors.

Authors:  G Zamboni; A Scarpa; G Bogina; C Iacono; C Bassi; G Talamini; F Sessa; C Capella; E Solcia; F Rickaert; G M Mariuzzi; G Klöppel
Journal:  Am J Surg Pathol       Date:  1999-04       Impact factor: 6.394

6.  Intraductal papillary mucinous tumors of the pancreas: pancreatic resections guided by preoperative morphological assessment and intraoperative frozen section examination.

Authors:  F Paye; A Sauvanet; B Terris; P Ponsot; V Vilgrain; P Hammel; P Bernades; P Ruszniewski; J Belghiti
Journal:  Surgery       Date:  2000-05       Impact factor: 3.982

7.  WHO-classification 2000: exocrine pancreatic tumors.

Authors:  G Klöppel; J Lüttges
Journal:  Verh Dtsch Ges Pathol       Date:  2001

8.  Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy.

Authors:  Philippe Lévy; Vincent Jouannaud; Dermot O'Toole; Anne Couvelard; Marie Pierre Vullierme; Laurent Palazzo; Alain Aubert; Philippe Ponsot; Alain Sauvanet; Frédérique Maire; Olivia Hentic; Pascal Hammel; Philippe Ruszniewski
Journal:  Clin Gastroenterol Hepatol       Date:  2006-04       Impact factor: 11.382

9.  Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor.

Authors:  Yutaka Suzuki; Yutaka Atomi; Masanori Sugiyama; Shuji Isaji; Kazuo Inui; Wataru Kimura; Makoto Sunamura; Toru Furukawa; Akio Yanagisawa; Jo Ariyama; Tadahiro Takada; Hidenobu Watanabe; Koichi Suda
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

Review 10.  Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms.

Authors:  Y M Shyr; C H Su; S H Tsay; W Y Lui
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

View more
  8 in total

Review 1.  White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.

Authors:  Naveen M Kulkarni; Lorenzo Mannelli; Marc Zins; Priya R Bhosale; Hina Arif-Tiwari; Olga R Brook; Elizabeth M Hecht; Fay Kastrinos; Zhen Jane Wang; Erik V Soloff; Parag P Tolat; Guillermo Sangster; Jason Fleming; Eric P Tamm; Avinash R Kambadakone
Journal:  Abdom Radiol (NY)       Date:  2020-03

Review 2.  Human correlates of provocative questions in pancreatic pathology.

Authors:  Oliver G McDonald; Anirban Maitra; Ralph H Hruban
Journal:  Adv Anat Pathol       Date:  2012-11       Impact factor: 3.875

3.  Determining the natural history of pancreatic cystic neoplasms: a Manitoban cohort study.

Authors:  Jon Broughton; Jeremy Lipschitz; Michael Cantor; Dana Moffatt; Ahmed Abdoh; Andrew McKay
Journal:  HPB (Oxford)       Date:  2016-01-29       Impact factor: 3.647

4.  Incidental Cystic Lesions in the Pancreas: Resect? EUS? Follow?

Authors:  Linda S Lee
Journal:  Curr Treat Options Gastroenterol       Date:  2014-09

5.  Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.

Authors:  Thula Cannon Walter; Ingo G Steffen; Lars H Stelter; Martin H Maurer; Marcus Bahra; Wladimir Faber; Fritz Klein; Hendrik Bläker; Bernd Hamm; Timm Denecke; Christian Grieser
Journal:  Eur Radiol       Date:  2014-11-30       Impact factor: 5.315

6.  Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer.

Authors:  Andrew H Nguyen; Paul A Toste; James J Farrell; Barbara M Clerkin; Jennifer Williams; V Raman Muthusamy; Rabindra R Watson; James S Tomlinson; O Joe Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2014-11-06       Impact factor: 3.452

7.  Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions.

Authors:  Dario de Biase; Michela Visani; Paola Baccarini; Anna Maria Polifemo; Antonella Maimone; Adele Fornelli; Adriana Giuliani; Nicola Zanini; Carlo Fabbri; Annalisa Pession; Giovanni Tallini
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 8.  Intraductal papillary mucinous neoplasm of the pancreas: an update.

Authors:  Shu-Yuan Xiao
Journal:  Scientifica (Cairo)       Date:  2012-11-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.